OncoSec Medical Inc. (ONCS) to Release Quarterly Earnings on Thursday
OncoSec Medical Inc. (NASDAQ:ONCS) will be issuing its Q416 quarterly earnings data on Thursday, October 13th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.
OncoSec Medical Inc. (NASDAQ:ONCS) opened at 1.72 on Wednesday. The stock has a 50 day moving average of $1.72 and a 200 day moving average of $1.84. OncoSec Medical Inc. has a 52 week low of $1.36 and a 52 week high of $4.61. The company’s market cap is $30.33 million.
ONCS has been the subject of a number of analyst reports. Maxim Group downgraded OncoSec Medical to a “buy” rating and dropped their price target for the company from $17.00 to $5.00 in a research note on Thursday, July 21st. Rodman & Renshaw initiated coverage on OncoSec Medical in a research note on Thursday, July 21st. They issued a “buy” rating and a $6.00 price target for the company.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/oncosec-medical-inc-oncs-to-release-quarterly-earnings-on-thursday.html
A hedge fund recently raised its stake in OncoSec Medical stock. Vanguard Group Inc. raised its stake in OncoSec Medical Inc. (NASDAQ:ONCS) by 3.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 430,031 shares of the company’s stock after buying an additional 13,025 shares during the period. Vanguard Group Inc. owned about 2.44% of OncoSec Medical worth $705,000 as of its most recent SEC filing. 7.42% of the stock is currently owned by institutional investors.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. The Company’s portfolio includes biologic immunology therapeutic product candidates intended to treat a range of tumor types.
Receive News & Ratings for OncoSec Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.